A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before

Abstract

Prevalence rate of diabetes mellitus worldwide and in Russian Federation is epidemic in its nature. Prospective studies have shown thatmaintenance of glycemic target reduces risk of late vascular complications. In turn, strict glycemic control requires modern approach tointensification of glucose lowering therapy. Randomized clinical trials prove capacity of modern insulin analogues to improve glycemiccontrol while decreasing risk of hypoglycemic events and weight gain. Current paper presents initial data on 9342 patients, participatedin multicenter prospective 52-week observational study A1chieve, conducted in order to assess efficiency and safety of treatment withinsulin analogues Levemir?, NovoMix? and NovoRapid? (Novo Nordisk) in daily management of patients with type 2 diabetes mellitus,who never received that treatment before.

Keywords

• diabetes mellitus type 2
• observational study a1chieve
• insulin analogues